<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081701</url>
  </required_header>
  <id_info>
    <org_study_id>1807019445</org_study_id>
    <nct_id>NCT04081701</nct_id>
  </id_info>
  <brief_title>68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.</brief_title>
  <acronym>DOMINO-START</acronym>
  <official_title>68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study population consists of patients who undergo resection for somatostatin
      receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including
      esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma,
      and SSTR-positive systemic cancers metastatic to the brain, such as small cell carcinoma of
      the lung. The study indication is to determine the diagnostic utility of 68Ga-DOTATATE
      PET/MRI in the diagnosis and management of patients with SSTR-positive CNS tumors,
      specifically whether 68Ga-DOTATATE PET/MRI demonstrates utility distinguishing between tumor
      recurrence and post-treatment change. To date, the utility of Ga-68-DOTATATE PET/MRI in
      meningioma has not been explored. Investigators have over the past 3 months been able to
      accrue the largest case series of presently 12 patients in whom Ga-68-DOTATATE PET/MRI
      demonstrated utility in the assessment of meningioma, including assessment for
      postsurgical/postradiation recurrence, detection of additional lesions not visualized on MRI
      alone, and evaluation of osseous invasion. Based on this initial experience, investigators
      intend to study the impact of Ga-68-DOTATATE PET/MRI in the assessment of the extent of
      residual tumor in patients status post meningioma resection, specifically in patients in whom
      tumor location limits resectability, patients with World Health Organization (WHO) grade
      II/III disease, and patients with history of stereotactic radiosurgery (SRS) who develop
      postradiation change.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the utility of Ga-68-DOTATATE PET/MRI in meningioma has not been explored.
      Investigators have over the past 3 months been able to accrue the largest case series of
      presently 12 patients in whom Ga-68 DOTATATE PET/MRI demonstrated utility in the assessment
      of meningioma, including assessment for postsurgical/postradiation recurrence, detection of
      additional lesions not visualized on MRI alone, and evaluation of osseous invasion. Based on
      this initial experience, investigators intend to study the impact of Ga-68-DOTATATE PET/MRI
      in the assessment of the extent of residual tumor in patients status post meningioma
      resection, specifically in patients in whom tumor location limits resectability, patients
      with WHO grade II/III disease, and patients with history of SRS who develop postradiation
      change.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate whether Ga-68-DOTATATE PET/MRI provides additional clinical benefit</measure>
    <time_frame>Longitudinal assessment up to 2 years</time_frame>
    <description>Diagnostic accuracy of Ga-68-DOTATATE PET/MRI will be compared to MRI alone. Correlative analyses will be performed including logistic regression/ Spearman correlation for continuous variables, and Mann-Whitney U tests for not normally distributed subgroups for variables allowing for dichotomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate Ga-68-DOTATATE PET/MR findings with histopathologic biomarker, SSTR2 expression</measure>
    <time_frame>Longitudinal assessment up to 2 years</time_frame>
    <description>Histopathologic biomarkers, including SSTR2 expression will be assessed for patients with meningioma, who undergo resection. Correlative analyses will be performed including logistic regression/ Spearman correlation for continuous variables, and Mann-Whitney U tests for not normally distributed subgroups for variables allowing for dichotomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Ga-68-DOTATATE PET/Magnetic Resonance(MR) findings with histopathologic biomarker, Ki67</measure>
    <time_frame>Longitudinal assessment up to 2 years</time_frame>
    <description>Histopathologic biomarkers, including Ki67 will be assessed for patients with meningioma, who undergo resection. Correlative analyses will be performed including logistic regression/ Spearman correlation for continuous variables, and Mann-Whitney U tests for not normally distributed subgroups for variables allowing for dichotomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Ga-68-DOTATATE PET/MR findings with histopathologic biomarker, progesterone receptor</measure>
    <time_frame>Longitudinal assessment up to 2 years</time_frame>
    <description>Histopathologic biomarkers, including progesterone receptor will be assessed for patients with meningioma, who undergo resection. Correlative analyses will be performed including logistic regression/ Spearman correlation for continuous variables, and Mann-Whitney U tests for not normally distributed subgroups for variables allowing for dichotomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Ga-68-DOTATATE PET/MR findings with histopathologic biomarker, epidermal growth factor receptor (EGFR)</measure>
    <time_frame>Longitudinal assessment up to 2 years</time_frame>
    <description>Histopathologic biomarkers, including EGFR will be assessed for patients with meningioma, who undergo resection. Correlative analyses will be performed including logistic regression/ Spearman correlation for continuous variables, and Mann-Whitney U tests for not normally distributed subgroups for variables allowing for dichotomization.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>CNS Tumors</condition>
  <condition>Meningioma</condition>
  <condition>Esthesioneuroblastoma</condition>
  <condition>Hemangioblastoma</condition>
  <condition>Medulloblastoma</condition>
  <condition>Paraganglioma</condition>
  <condition>Pituitary Adenoma</condition>
  <arm_group>
    <arm_group_label>Meningioma</arm_group_label>
    <description>Cohort of 30 subjects with meningioma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Meningioma</arm_group_label>
    <description>Cohort of 60 subjects with non-meningioma:
(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ga68-DOTATATE-PET/MRI</intervention_name>
    <description>In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.
In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.</description>
    <arm_group_label>Meningioma</arm_group_label>
    <arm_group_label>Non-Meningioma</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Molecular biomarkers will be assessed including SSTR2, Ki-67, EGFR expression, and
      progesterone receptor expression.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patient cohort will consist of individuals who undergo resection for SSTR-positive CNS
        tumors, including meningioma, esthesioneuroblastoma, hemangioblastoma, medulloblastoma,
        paraganglioma, pituitary adenoma, and SSTR-positive tumors metastatic to the brain, and in
        whom tumor recurrence versus post treatment change is questioned for reasons including, but
        not limited to, high WHO grade, suspected subtotal resection based on tumor location, or
        positive surgical margins. Subjects with diagnosis of meningioma specifically in patients
        in whom tumor location limits gross total resectability (for example in the skullbase,
        sphenoid wing, spheno-orbital location) and patients who have WHO grade II/ III disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age

          -  Diagnosis of meningioma based on pathology reports and suspected recurrence or
             residual disease based on standard-of-care MRI

          -  Additionally, patients with other somatostatin receptor 2 positive brain tumors,
             including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma,
             pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain will be
             considered for the purposes of obtaining feasibility data

          -  As the investigator's institution, PET/MRI scanner utilizes a 3 Tesla (T) magnet,
             patients who may be ineligible to undergo 3T MRI but may undergo 1.5 Tesla (T) MRI,
             will undergo a 1.5T MRI as per clinical standard-of-care and a Ga68-DOTATATE PET/CT
             with the PET portion to be fused with the 1.5T MRI utilizing fusion software.

        Exclusion Criteria:

          -  Contraindications to gadolinium-based contrast agent

          -  History of allergic reaction to Gallium-68-DOTATATE

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana Ivanidze, MD/Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana Ivanidze, MD/Ph.D</last_name>
    <phone>212-746-4587</phone>
    <email>jai9018@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jana Ivanidze</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Ivanidze, MD/Ph.D</last_name>
      <phone>212-746-4587</phone>
      <email>jai9018@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Esthesioneuroblastoma, Olfactory</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Hemangioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

